Biosimilar Pipeline And Global Expansion Will Unlock Future Opportunities
AN
AnalystConsensusTarget
Not Invested
Consensus Narrative from 14 Analysts
Published
17 Aug 25
Updated
17 Aug 25
AnalystConsensusTarget's Fair Value
CHF 49.14
2.2% overvalued intrinsic discount17 Aug
CHF 50.22
1Y
33.8%7D
4.8%